Author
1. Munjal Yash Pal
2. Prakash Anupam
ISBN
9789354656361
DOI
10.5005/jp/books/18786_107
Edition
12/e
Publishing Year
2022
Pages
5
Author Affiliations
1.
Banarsidas Chandiwala Institute of Medical Science, Kalkaji, New Delhi,
Artemis Hospital, Gurugram, Haryana, India,
Artemis Hospital, Gurugram, Haryana, India; Banarsidas, Chandiwala Institute of Medical Sciences, Kalkaji, New Delhi, India
2.
Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, India,
Lady Hardinge Medical College and SK Hospital, New Delhi,
Lady Hardinge Medical College and SSK Hospital, New Delhi, India,
Lady Hardinge Medical College, New Delhi, India,
Lady Hardinge Medical College and Smt Sucheta Kriplani Hospital, New Delhi, India,
Lady Hardinge Medical College and Associate Hospitals, New Delhi, India,
Lady Hardinge Medical College and Associated Hospitals, New Delhi, India
Chapter keywords
Oral antidiabetic drug,
incretin-based treatment,
SGLT-2 inhibitor,
type 1 diabetes mellitus,
T1DM,
type 2 diabetes mellitus,
T2DM,
glucagon-like peptide-1,
atherosclerotic cardiovascular disease,
amylin analog,
miscellaneous agent